2017 Q4 Form 10-K Financial Statement
#000119312520044221 Filed on February 21, 2020
Income Statement
| Concept | 2017 Q4 |
|---|---|
| Revenue | $5.459B |
| YoY Change | -15.91% |
| Cost Of Revenue | $3.127B |
| YoY Change | -5.47% |
| Gross Profit | $2.444B |
| YoY Change | -27.91% |
| Gross Profit Margin | 44.77% |
| Selling, General & Admin | $935.0M |
| YoY Change | -29.01% |
| % of Gross Profit | 38.26% |
| Research & Development | $346.0M |
| YoY Change | -46.77% |
| % of Gross Profit | 14.16% |
| Depreciation & Amortization | $528.0M |
| YoY Change | 59.04% |
| % of Gross Profit | 21.6% |
| Operating Expenses | $1.364B |
| YoY Change | -24.85% |
| Operating Profit | $1.080B |
| YoY Change | -31.43% |
| Interest Expense | -$286.0M |
| YoY Change | -63.19% |
| % of Operating Profit | -26.48% |
| Other Income/Expense, Net | $95.00M |
| YoY Change | |
| Pretax Income | -$13.21B |
| YoY Change | 1345.08% |
| Income Tax | -$410.0M |
| % Of Pretax Income | |
| Net Earnings | -$11.54B |
| YoY Change | 1085.51% |
| Net Earnings / Revenue | -211.3% |
| Basic Earnings Per Share | -$11.41 |
| Diluted Earnings Per Share | -$11.41 |
| COMMON SHARES | |
| Basic Shares Outstanding | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q4 |
|---|---|
| SHORT-TERM ASSETS | |
| Cash & Short-Term Investments | $963.0M |
| YoY Change | -2.53% |
| Cash & Equivalents | $963.0M |
| Short-Term Investments | |
| Other Short-Term Assets | $701.0M |
| YoY Change | -81.37% |
| Inventory | $4.924B |
| Prepaid Expenses | $1.100B |
| Receivables | $7.128B |
| Other Receivables | $0.00 |
| Total Short-Term Assets | $15.38B |
| YoY Change | -10.72% |
| LONG-TERM ASSETS | |
| Property, Plant & Equipment | $7.673B |
| YoY Change | -4.95% |
| Goodwill | $28.41B |
| YoY Change | -36.02% |
| Intangibles | $17.64B |
| YoY Change | -17.9% |
| Long-Term Investments | |
| YoY Change | |
| Other Assets | $932.0M |
| YoY Change | -24.53% |
| Total Long-Term Assets | $55.23B |
| YoY Change | -27.16% |
| TOTAL ASSETS | |
| Total Short-Term Assets | $15.38B |
| Total Long-Term Assets | $55.23B |
| Total Assets | $70.62B |
| YoY Change | -24.12% |
| SHORT-TERM LIABILITIES | |
| YoY Change | |
| Accounts Payable | $2.069B |
| YoY Change | -4.08% |
| Accrued Expenses | $3.563B |
| YoY Change | -16.44% |
| Deferred Revenue | |
| YoY Change | |
| Short-Term Debt | $1.000M |
| YoY Change | -93.33% |
| Long-Term Debt Due | $2.880B |
| YoY Change | 255.56% |
| Total Short-Term Liabilities | $17.92B |
| YoY Change | -3.07% |
| LONG-TERM LIABILITIES | |
| Long-Term Debt | $28.83B |
| YoY Change | -11.36% |
| Other Long-Term Liabilities | $1.843B |
| YoY Change | 12.45% |
| Total Long-Term Liabilities | $33.95B |
| YoY Change | -14.22% |
| TOTAL LIABILITIES | |
| Total Short-Term Liabilities | $17.92B |
| Total Long-Term Liabilities | $33.95B |
| Total Liabilities | $51.87B |
| YoY Change | -10.67% |
| SHAREHOLDERS EQUITY | |
| Retained Earnings | -$3.803B |
| YoY Change | -127.95% |
| Common Stock | $54.00M |
| YoY Change | 0.0% |
| Preferred Stock | |
| YoY Change | |
| Treasury Stock (at cost) | $4.149B |
| YoY Change | -1.07% |
| Treasury Stock Shares | 107.0M shares |
| Shareholders Equity | $17.36B |
| YoY Change | |
| Total Liabilities & Shareholders Equity | $70.62B |
| YoY Change | -24.12% |
Cashflow Statement
| Concept | 2017 Q4 |
|---|---|
| OPERATING ACTIVITIES | |
| Net Income | -$11.54B |
| YoY Change | 1085.51% |
| Depreciation, Depletion And Amortization | $528.0M |
| YoY Change | 59.04% |
| Cash From Operating Activities | $859.0M |
| YoY Change | 854.44% |
| INVESTING ACTIVITIES | |
| Capital Expenditures | -$267.0M |
| YoY Change | -19.82% |
| Acquisitions | |
| YoY Change | |
| Other Investing Activities | $2.179B |
| YoY Change | 150.17% |
| Cash From Investing Activities | $1.912B |
| YoY Change | 255.39% |
| FINANCING ACTIVITIES | |
| Cash Dividend Paid | |
| YoY Change | |
| Common Stock Issuance & Retirement, Net | |
| YoY Change | |
| Debt Paid & Issued, Net | |
| YoY Change | |
| Cash From Financing Activities | -2.506B |
| YoY Change | 257.49% |
| NET CHANGE | |
| Cash From Operating Activities | 859.0M |
| Cash From Investing Activities | 1.912B |
| Cash From Financing Activities | -2.506B |
| Net Change In Cash | 265.0M |
| YoY Change | -463.01% |
| FREE CASH FLOW | |
| Cash From Operating Activities | $859.0M |
| Capital Expenditures | -$267.0M |
| Free Cash Flow | $1.126B |
| YoY Change | 166.19% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019 | dei |
Entity Registrant Name
EntityRegistrantName
|
TEVA PHARMACEUTICAL INDUSTRIES LTD | |
| CY2019 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
IL | |
| CY2019 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
00-0000000 | |
| CY2019 | dei |
Entity Address Country
EntityAddressCountry
|
IL | |
| CY2019 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
| CY2019 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
97000000 | |
| CY2018 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-713000000 | |
| CY2017 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1516000000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
||
| CY2018 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
-52000000 | |
| CY2019 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
||
| CY2018 | us-gaap |
Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
|
12000000 | |
| CY2017 | us-gaap |
Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
|
901000000 | |
| CY2019 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
52000000 | |
| CY2018 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
10000000 | |
| CY2017 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
260000000 | |
| CY2017Q4 | us-gaap |
Goodwill
Goodwill
|
28414000000 | |
| CY2018 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
3027000000 | |
| CY2018 | us-gaap |
Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
|
79000000 | |
| CY2018Q4 | us-gaap |
Goodwill
Goodwill
|
24917000000 | |
| CY2019Q4 | us-gaap |
Goodwill
Goodwill
|
24846000000 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-115000000 | |
| CY2018 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
381000000 | |
| CY2017 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
3817000000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
|
1733000000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
|
2282000000 | |
| CY2019Q4 | teva |
Deferred Tax Assets Carryforward Losses And Deductions Noncurrent
DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent
|
1689000000 | |
| CY2018Q4 | teva |
Deferred Tax Assets Carryforward Losses And Deductions Noncurrent
DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent
|
1340000000 | |
| CY2019 | us-gaap |
Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
|
50000000 | |
| CY2018 | us-gaap |
Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
|
67000000 | |
| CY2017 | us-gaap |
Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
|
1083000000 | |
| CY2019 | teva |
Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
|
5000000 | |
| CY2018 | teva |
Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
|
195000000 | |
| CY2017 | teva |
Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
|
83000000 | |
| CY2019 | teva |
Venezuela Devaluation Charge
VenezuelaDevaluationCharge
|
0 | |
| CY2018 | teva |
Venezuela Devaluation Charge
VenezuelaDevaluationCharge
|
0 | |
| CY2017 | teva |
Venezuela Devaluation Charge
VenezuelaDevaluationCharge
|
42000000 | |
| CY2019 | teva |
Other Financial Income Expense Net
OtherFinancialIncomeExpenseNet
|
4000000 | |
| CY2018 | teva |
Other Financial Income Expense Net
OtherFinancialIncomeExpenseNet
|
-65000000 | |
| CY2017 | teva |
Other Financial Income Expense Net
OtherFinancialIncomeExpenseNet
|
3000000 | |
| CY2019Q4 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
460000000 | |
| CY2018Q4 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
507000000 |
